Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind placebo-controlled Phase 2 trial of rBet v1-FV in birch pollen allergy
2008-006258-16Phase 2Completed
- Sponsor
- Allergopharma
- Start
- Nov 2008
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in allergic rhinitis (AR), asthma and birch pollen allergy comparing rBet v1-FV immunotherapy with Placebo (2 arms). Primary endpoints: Immunohistological changes in cell populations and Tolerability and safety of rBet v1-FV. Started Nov 2008; status: completed.
02
Drugs
rBet v1-FV
03
Conditions
allergic rhinitis (AR)asthmabirch pollen allergy
Beyond the preview
Go deeper on 2008-006258-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006258-16.